stocks
Moderna Doubles in a Day: How One Trial Result Reset a $25 Billion Stock
Moderna shares surged as much as 177% after a landmark melanoma vaccine trial with Merck. What the data showed and what Wall Street thinks it's worth.
Author
Sophie Harcourt
Equities & Earnings Writer, Global Markets Review
Sophie Harcourt is an equities and earnings writer at Global Markets Review, covering listed companies, quarterly results and the events that move individual stocks. Her reporting focuses on earnings releases, corporate outlooks, IPOs, sector trends and changes in investor expectations.
She follows companies across the US, UK and European markets, examining the numbers behind each announcement and what they reveal about valuations, growth prospects and the wider competitive landscape.
Her approach to sell-side research is deliberately sceptical: she treats price-target changes and rating changes as different events, and leans on primary documents — quarterly reports, investor-relations calendars and regulatory filings — rather than secondary commentary.
Sophie Harcourt holds no positions in individual securities covered by Global Markets Review.
Articles by Sophie Harcourt
earnings
Walmart, Target and Home Depot Earnings This Week Will Test How Resilient the US Consumer Really Is
Six major retailers report this week. Here's what Walmart, Target and Home Depot earnings will reveal about the US consumer heading into fall.
markets
European Stocks Are at Record Highs — and It's Not the Names You'd Expect
The FTSE, DAX, CAC 40 and STOXX 600 are all at record highs in 2026, led by chip-equipment stocks rather than luxury or pharma names.
markets
The S&P 500 Is at a Record. Ten Stocks Are Doing Most of the Work.
The S&P 500 and Nasdaq are at record highs, but a handful of AI-linked megacaps drive the gains. What concentration means for US stock investors.
earnings
The Q3 Earnings Calendar That Actually Matters
A guide to the Q3 2026 earnings calendar — key reporting dates, consensus EPS estimates and the guidance lines that move markets.
markets
The FTSE 100 Is Cheap for a Reason — and It Still Might Be Too Cheap
UK and European stocks trade at a persistent discount to US equities. What index composition explains, what it doesn't, and where the value sits.
stocks
TSMC’s Record Profit Shows the AI Chip Cycle Is Still a Capacity Story
TSMC’s record Q2 profit expectations and advanced-node demand show why AI semiconductor growth remains constrained by manufacturing capacity.
earnings
Nike's China Slump Shows Why Its Turnaround Is Taking Longer Than Investors Hoped
Nike beat quarterly expectations, but a 17% Greater China sales decline and weak outlook show its turnaround remains unfinished.